A Feasibility Study on the Use of Equine Chondrogenic Induced Mesenchymal Stem Cells as a Treatment for Natural Occurring Osteoarthritis in Dogs

Daems, Robert; Hecke, Lore Van; Schwarzkopf, Ilona; Depuydt, Eva; Broeckx, Sarah; David, Michael A.; Beerts, Charlotte; Vandekerckhove, Peter; Spaas, Jan H.

doi:10.1155/2019/4587594

Cited by 24 publications

(53 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight human studies (Jancewicz et al, 2004;Saw et al, 2011;Skowroński et al, 2012;Saw et al, 2013;Skowroński and Rutka, 2013;Turajane et al, 2013;Fu et al, 2014a;Saw et al, 2015) and 1 animal (Hopper et al, 2015b) study used autologous noncultureexpanded condensed PBSCs, 1 animal study (Deng et al, 2015) used allogenic condensed PBSCs, 1 animal study (Spaas et al, 2012) used autologous culture-expanded PB-MSCs, 6 animal studies (Broeckx et al, 2014a;Broeckx et al, 2014b;Fu et al, 2014b;Zhao et al, 2018;Broeckx et al, 2019a;Broeckx et al, 2019b) used allogenic culture-expanded PB-MSCs, and 1 animal study (Daems et al, 2019) used xenogeneic culture-expanded PB-MSCs as seed cells for cartilage repair and regeneration.…”

Section: Stem Cell Types and Isolation Methodsmentioning

confidence: 99%

“…One animal study (Deng et al, 2015) with 28 Sprague-Dawley (SD) rats used the density gradient centrifugation (DGC) method to isolate PBSCs. Eight animal studies (Spaas et al, 2012;Broeckx et al, 2014a;Broeckx et al, 2014b;Hopper et al, 2015b;Zhao et al, 2018;Daems et al, 2019;Broeckx et al, 2019a;Broeckx et al, 2019b) with 272 horses, 24 mountain sheep, 12 Diannan small-ear pigs, and 6 dogs used the DGC and plastic adherence (PA) methods to isolate PB-MSCs and PBSCs. Furthermore, one animal study (Fu et al, 2014b) with 30 New Zealand White rabbits used the erythrocyte lysis and PA methods to isolate PB-MSCs.…”

Section: Stem Cell Types and Isolation Methodsmentioning

confidence: 99%

“…All reference lists of the 17 included studies were investigated, and an additional human trial (Jancewicz et al, 2004) was identified and included in this review. Finally, data from the 18 studies [8 human studies (Jancewicz et al, 2004;Saw et al, 2011;Skowroński et al, 2012;Saw et al, 2013;Skowroński and Rutka, 2013;Turajane et al, 2013;Fu et al, 2014a;Saw et al, 2015) and 10 animal studies (Spaas et al, 2012;Broeckx et al, 2014a;Broeckx et al, 2014b;Fu et al, 2014a;Deng et al, 2015;Hopper et al, 2015b;Zhao et al, 2018;Daems et al, 2019;Broeckx et al, 2019a;Broeckx et al, 2019b) published by investigators from seven countries or regions] were analyzed.…”

Section: Description Of the Included Studiesmentioning

confidence: 99%

“…Among the 18 studies, 7 were case reports [6 in humans (Jancewicz et al, 2004;Saw et al, 2011;Skowroński et al, 2012;Turajane et al, 2013;Fu et al, 2014a;Saw et al, 2015) and 1 in horses (Spaas et al, 2012)], 1 was a human comparative study (Skowroński and Rutka, 2013), 1 was a human randomized controlled trial (RCT) (Saw et al, 2013), 1 was a preliminary study (in horses) (Broeckx et al, 2014a), 1 was a pilot study (in horses) (Broeckx et al, 2014b), 4 involved animal models [rabbits (Fu et al, 2014b), sheep (Hopper et al, 2015b), rats (Deng et al, 2015), and pigs (Zhao et al, 2018), 1 was a prospective placebocontrolled study (in dog) (Daems et al, 2019), and 2 were randomized, double-blinded, placebo-controlled proof-ofconcept study (in horses) (Broeckx et al, 2019a;Broeckx et al, 2019b) (Table 1). (Jancewicz et al, 2004) Human 9Case report N/A N/A Osteochondral defects Talus 0.5×0.7 cm with 0.5-1.0 cm depth ICRS IV (Skowroński et al, 2012 The age of the patients ranged from 7 to 59 years in the 8 human studies (Jancewicz et al, 2004;Saw et al, 2011;Skowroński et al, 2012;Saw et al, 2013;Skowroński and Rutka, 2013;Turajane et al, 2013;Fu et al, 2014a;Saw et al, 2015).…”

Section: Description Of the Included Studiesmentioning

confidence: 99%

“…The International Cartilage Repair Society (ICRS) scores were all grade III-IV (Jancewicz et al, 2004;Saw et al, 2011;Skowroński et al, 2012;Saw et al, 2013;Skowroński and Rutka, 2013;Turajane et al, 2013;Fu et al, 2014a;Saw et al, 2015). Types of lesions included spontaneous and induced osteoarthritis (Spaas et al, 2012;Broeckx et al, 2014a;Broeckx et al, 2014b;Deng et al, 2015;Daems et al, 2019;Broeckx et al, 2019a;Broeckx et al, 2019b), cartilage defects (Zhao et al, 2018), and osteochondral defects (Fu et al, 2014b;Hopper et al, 2015b) in the 10 animal studies. The lesions were in the knee joint (Broeckx et al, 2014a;Fu et al, 2014b;Deng et al, 2015;Hopper et al, 2015b;Zhao et al, 2018), fetlock joint (Broeckx et al, 2014a;Broeckx et al, 2014b;Broeckx et al, 2019a;Broeckx et al, 2019b), pastern joint (Broeckx et al, 2014a), coffin joint (Broeckx et al, 2014b), and humeroradial joint (Daems et al, 2019).…”

Section: Description Of the Included Studiesmentioning

confidence: 99%

See 4 more Smart Citations

The Use of Peripheral Blood-Derived Stem Cells for Cartilage Repair and Regeneration In Vivo: A Review

et al. 2020

View full text Add to dashboard Cite

Background: Peripheral blood (PB) is a potential source of chondrogenic progenitor cells that can be used for cartilage repair and regeneration. However, the cell types, isolation and implantation methods, seeding dosage, ultimate therapeutic effect, and in vivo safety remain unclear. Methods: PubMed, Embase, and the Web of Science databases were systematically searched for relevant reports published from January 1990 to December 2019. Original articles that used PB as a source of stem cells to repair cartilage in vivo were selected for analysis. Results: A total of 18 studies were included. Eight human studies used autologous nonculture-expanded PB-derived stem cells (PBSCs) as seed cells with the blood cell separation isolation method, and 10 animal studies used autologous, allogenic or xenogeneic culture-expanded PB-derived mesenchymal stem cells (PB-MSCs), or nonculture-expanded PBSCs as seed cells. Four human and three animal studies surgically implanted cells, while the remaining studies implanted cells by single or repeated intra-articular injections. 121 of 130 patients (in 8 human clinical studies), and 230 of 278 animals (in 6 veterinary clinical studies) using PBSCs for cartilage repair achieved significant clinical improvement. All reviewed articles indicated that using PB as a source of seed cells enhances cartilage repair in vivo without serious adverse events. Conclusion: Autologous nonculture-expanded PBSCs are currently the most commonly used cells among all stem cell types derived from PB. Allogeneic, autologous, and xenogeneic PB-MSCs are more widely used in animal studies and are potential seed cell types for future applications. Improving the mobilization and purification technology, and shortening the culture cycle of culture-expanded PB-MSCs will obviously promote the researchers' interest. The use of PBSCs for cartilage repair and regeneration in vivo are safe. PBSCs considerably warrant further investigations due to their superiority and safety in clinical settings and positive effects despite limited evidence in humans.

show abstract

Section: Stem Cell Types and Isolation Methodsmentioning

confidence: 99%

Section: Stem Cell Types and Isolation Methodsmentioning

confidence: 99%

Section: Description Of the Included Studiesmentioning

confidence: 99%

Section: Description Of the Included Studiesmentioning

confidence: 99%

Section: Description Of the Included Studiesmentioning

confidence: 99%

See 3 more Smart Citations

The Use of Peripheral Blood-Derived Stem Cells for Cartilage Repair and Regeneration In Vivo: A Review

et al. 2020

View full text Add to dashboard Cite

show abstract

Clinical Management and Pharmacologic Treatment of Pain

McKune

2024

Veterinary Anesthesia and Analgesia

View full text Add to dashboard Cite

Cell‐based therapies have disease‐modifying effects on osteoarthritis in animal models: A systematic review by the ESSKA Orthobiologic Initiative. Part 3: Umbilical cord, placenta, and other sources for cell‐based injectable therapies

Sourugeon,

Boffa,

Perucca Orfei

et al. 2024

Knee surg. sports traumatol. arthrosc.

View full text Add to dashboard Cite

PurposeThis systematic review aimed to investigate in animal models the presence of disease‐modifying effects driven by non‐bone marrow‐derived and non‐adipose‐derived products, with a particular focus on umbilical cord and placenta‐derived cell‐based therapies for the intra‐articular injective treatment of osteoarthritis (OA).MethodsA systematic review was performed on three electronic databases (PubMed, Web of Science and Embase) according to PRISMA guidelines. The results were synthesised to investigate disease‐modifying effects in preclinical animal studies comparing injectable umbilical cord, placenta, and other sources‐derived products with OA controls. The risk of bias was assessed using the SYRCLE tool.ResultsA total of 80 studies were included (2314 animals). Cell therapies were most commonly obtained from the umbilical cord in 33 studies and placenta/amniotic tissue in 18. Cell products were xenogeneic in 61 studies and allogeneic in the remaining 19 studies. Overall, 25/27 (92.6%) of studies on umbilical cord‐derived products documented better results compared to OA controls in at least one of the following outcomes: macroscopic, histological and/or immunohistochemical findings, with 19/22 of studies (83.4%) show positive results at the cartilage level and 4/6 of studies (66.7%) at the synovial level. Placenta‐derived injectable products documented positive results in 13/16 (81.3%) of the studies, 12/15 (80.0%) at the cartilage level, and 2/4 (50.0%) at the synovial level, but 2/16 studies (12.5%) found overall worse results than OA controls. Other sources (embryonic, synovial, peripheral blood, dental pulp, cartilage, meniscus and muscle‐derived products) were investigated in fewer preclinical studies. The risk of bias was low in 42% of items, unclear in 49%, and high in 9% of items.ConclusionInterest in cell‐based injectable therapies for OA treatment is soaring, particularly for alternatives to bone marrow and adipose tissue. While expanded umbilical cord mesenchymal stem cells reported auspicious disease‐modifying effects in preventing OA progression in animal models, placenta/amniotic tissue also reported deleterious effects on OA joints. Lower evidence has been found for other cellular sources such as embryonic, synovial, peripheral blood, dental‐pulp, cartilage, meniscus, and muscle‐derived products.Level of EvidenceLevel II.

show abstract

A Feasibility Study on the Use of Equine Chondrogenic Induced Mesenchymal Stem Cells as a Treatment for Natural Occurring Osteoarthritis in Dogs

Cited by 24 publications

References 31 publications

The Use of Peripheral Blood-Derived Stem Cells for Cartilage Repair and Regeneration In Vivo: A Review

The Use of Peripheral Blood-Derived Stem Cells for Cartilage Repair and Regeneration In Vivo: A Review

Clinical Management and Pharmacologic Treatment of Pain

Cell‐based therapies have disease‐modifying effects on osteoarthritis in animal models: A systematic review by the ESSKA Orthobiologic Initiative. Part 3: Umbilical cord, placenta, and other sources for cell‐based injectable therapies

Contact Info

Product

Resources

About